Revvity, Inc. (RVTY) Stock Analysis and Metrics

Revvity

NYSE: RVTY

$111.02 ▼ -1.27 (-1.13%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap12.62 Bn

P/E21,946.33

P/S4.35

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)3.21 Bn

Revenue Growth (1y) (Qtr)6.97

Add ratio to table…

About

Revvity is a leading provider of health science solutions technologies expertise and services that deliver complete workflows from discovery to development and diagnosis to cure. The company focuses on translational multi omics technologies biomarker identification imaging prediction screening detection diagnosis informatics and related areas. Headquartered in Waltham Massachusetts Revvity markets its products and services in more than 160 countries worldwide. As of December 28 2025 it employed approximately 11000 employees.

Revvity generates revenue through the sale of reagents instruments software and technology licensing offerings. Its product portfolio includes radiometric detection reagents microscopy imaging reagents homogeneous biochemical and cell based assay kits recombinant cell lines gene modulation tools immunoassay reagents and a broad array of antibodies. Instruments range from scintillation analyzers and high content imaging systems to automated liquid handling platforms ultrasound devices and cell counters. Software solutions cover high content imaging analysis data management electronic lab notebooks chemical drawing tools clinical trial platforms and AI enabled analytics. Technology and licensing revenues arise from proprietary platforms such as base editing systems expression platforms gene delivery services and preclinical service offerings. Customers include life science researchers pharmaceutical biotech and contract research organizations academic and government institutions as well as hospitals medical labs clinicians and diagnostic laboratories.

The company operates through the following segments: Life Sciences and Diagnostics.

• The Life Sciences segment provides a comprehensive portfolio that helps researchers understand disease mechanisms and develop treatments. It offers reagents such as radiometric detection chemicals microscopy imaging reagents homogeneous biochemical and cell based assay kits recombinant GPCR and ion channel cell lines gene modulation tools immunoassay reagents and antibodies. Instruments include scintillation analyzers high content imaging systems automated liquid handling platforms ultrasound systems and cell counters. Software includes high content imaging analysis data management electronic lab notebooks chemical drawing tools clinical trial platforms and AI enabled analytics. Technology and licensing cover base editing platforms expression systems gene delivery services and preclinical service offerings. The segment serves global pharmaceutical biotech contract research organizations academic and government institutions.

• The Diagnostics segment supplies instruments reagents assay platforms and software to hospitals medical labs clinicians and medical research professionals. Its focus areas include reproductive health immunodiagnostics and emerging market diagnostics. Products encompass prenatal and maternal health screening kits newborn screening metabolic disorder assays infectious disease testing platforms chemiluminescence immunoassays autoimmune testing tools and genomic workflow solutions based on PCR and next generation sequencing. The segment supports early detection of conditions such as Down syndrome hypothyroidism muscular dystrophy infertility and various metabolic disorders. It also provides products for oncology immunodiagnostics and drug discovery applications.

Revvity holds a strong position in the health science solutions market due to its broad integrated product portfolio global reach and sustained investment in research development and acquisitions. The company competes with a wide range of participants from large multinational corporations that offer diversified life sciences and diagnostics portfolios to specialized firms that concentrate on niche markets. Competitive advantages stem from its ability to deliver end to end workflow solutions its technological innovation in areas such as multi omics imaging and AI enhanced analytics and its extensive sales and service presence in over 160 countries. The firm also benefits from a diversified customer base that reduces reliance on any single market segment and from a disciplined approach to capital allocation that supports organic growth strategic acquisitions and shareholder returns.

Revvity serves a diverse customer base that includes life science researchers at pharmaceutical biotech and contract research organizations academic and government institutions hospitals medical labs clinicians diagnostic laboratories expectant mothers and newborn screening programs. Specific customer names are not disclosed in the filing but the company reports that its products are used in more than 160 countries across a variety of end markets.

Investment Thesis

▲ Bull case

The company's strategic decision to divest its low-margin, slow-growth immunodiagnostics business in China represents a transformative capital allocation that will significantly enhance core profitability and growth trajectory. Management explicitly stated this removal will improve 2026 total company organic growth by approximately 100 basis points and operating margins by 30 basis points, but the bullish case is far stronger as the divestiture eliminates a persistent drag on cash flow conversion and disproportionate management focus, freeing resources for higher-return initiatives. The pro forma Q1 organic growth of 6% (vs. reported 3%) and adjusted operating margin of 24% (vs. reported 23.6%) demonstrate the immediate quality improvement of the core business, with management noting that excluding this business, pro forma organic growth would have been 6% and margins 24% in Q1 – a clear indication that the underlying Life Sciences and Diagnostics segments are fundamentally stronger than headline numbers suggest. This strategic pruning directly supports the long-range plan targeting 6%-8% organic growth and double-digit EPS growth by sharpening focus on areas with clear competitive advantages and healthy growth trajectories, particularly the Life Sciences business in China which continued to perform well with reagents growing solidly above overall reagents performance last year despite the immunodiagnostic headwinds. Furthermore, the company is positioned to capitalize on structural inflection points in AI-driven life sciences research, where every AI-generated discovery requires physical validation through wet lab experimentation – creating a demand bottleneck for Revvity's core offerings in consumables, instruments, and software that translate computational insights into biological validation. The internal AI deployment, highlighted by Gartner research as differentiated and cost-effective, is accelerating software delivery and enabling previously infeasible initiatives at a fraction of traditional implementation costs, with employee adoption rates well above corporate averages, signaling immediate operational efficiency gains that will compound as cost productivity initiatives fully roll out by midyear, driving margin expansion starting in the second half of 2026 and annualizing into robust first-half 2027 performance. Recent FDA clearance for Revvity's Total Testosterone automated chemiluminescence immunoassay completes a first-of-its-kind testosterone diagnostics portfolio on a single platform, streamlining workflow and replacing complex ED-LC/MS methods, which addresses a critical unmet need in endocrine disorders and expands the company's reproductive health franchise beyond its current strength in newborn screening and Genomics England contributions – a near-term catalyst management understated amid broader AI and software discussions. The combination of portfolio optimization, AI-driven demand inflection, operational efficiency execution, and new product launches in high-growth software (BioDesign, LabGistics, Xynthetica) creates a powerful convergence of catalysts that the market is underestimating as it focuses narrowly on near-term guidance ranges rather than the multi-year value creation phase of AI adoption in life sciences where Revvity holds enabling technologies.
Revvity's software segment, particularly the Signals business, is experiencing a hidden inflection point in adoption and monetization that is not fully captured by organic growth metrics due to acquisition-related revenue recognition timing, presenting a significant bullish catalyst for future revenue acceleration and margin expansion. While management noted organic growth for software is expected to be positive mid-single digits for the full year and acknowledged a 20% Q2 decline due to tough comps, they simultaneously highlighted robust SaaS and ARR growth north of 30% in Q1 and strong double-digit APV (Annualized Contract Value) growth, indicating that the underlying customer acquisition and contract value momentum is substantially stronger than organic growth suggests – a discrepancy driven by the timing of revenue recognition from recent acquisitions like ACD/Labs, which contributed 75 basis points to Q1 revenue growth but masks the true velocity of the software franchise. The excitement around upcoming launches – Xynthetica (AI models as a service), BioDesign (cloud-native molecular design for biologics), and LabGistics (AI-first drug discovery workflow) – represents a rare confluence of innovation where all three major software products are launching in a single year, creating a comprehensive suite that addresses critical needs in AI-driven preclinical R&D, from computational hypothesis generation to wet lab validation workflows, with BioDesign being the only cloud-based offering of its type at launch, positioning Revvity to capture early-mover advantage in a rapidly expanding market. This software-led growth is further amplified by the company's differentiated internal AI adoption strategy, which uses a structured approach to deploy multiple leading LLMs across the global employee base at a fraction of traditional corporate AI costs, yielding productivity gains that are already accelerating software delivery and enabling impactful initiatives – a cost-efficient engine for innovation that management believes will have a remarkable cost-out impact in the mid- to longer term, directly contributing to operating margin expansion beyond the current 28.4% pro forma target as these initiatives scale and anniversary through 2027. The market is overlooking how this software innovation cycle, combined with the secular tailwind of AI increasing demand for biological validation tools, creates a self-reinforcing loop: AI-generated therapeutic hypotheses drive demand for wet lab experimentation (Revvity's core), which in turn generates new data that improves AI models, thereby increasing the value of Revvity's software and instrument offerings that facilitate this cycle – a virtuous cycle where the company sits at the nexus of value creation in the AI adoption journey, with significant upside potential as the market transitions from infrastructure build-out to value capture phase, where customers realize returns on AI investments through faster timelines and higher success rates, incentivizing even greater investment in research capabilities and expanding the total addressable market for scientific tools. This structural shift in how preclinical research is conducted – where AI accelerates hypothesis generation but physical validation remains irreplaceable – ensures sustained demand for Revvity's offerings regardless of short-term macroeconomic fluctuations, providing a durable growth runway that is not reflected in the conservative 3%-4% pro forma organic guidance for 2026.

The company's strategic decision to divest its low-margin, slow-growth immunodiagnostics business in China represents a transformative capital allocation that will significantly enhance core profitability and growth trajectory. Management explicitly stated this removal will improve 2026 total company organic growth by approximately 100 basis points and operating margins by 30 basis points, but the bullish case is far stronger as the divestiture eliminates a persistent drag on cash flow conversion and disproportionate management focus, freeing resources for higher-return initiatives. The pro forma Q1 organic growth of 6% (vs. reported 3%) and adjusted operating margin of 24% (vs. reported 23.6%) demonstrate the immediate quality improvement of the core business, with management noting that excluding this business, pro forma organic growth would have been 6% and margins 24% in Q1 – a clear indication that the underlying Life Sciences and Diagnostics segments are fundamentally stronger than headline numbers suggest. This strategic pruning directly supports the long-range plan targeting 6%-8% organic growth and double-digit EPS growth by sharpening focus on areas with clear competitive advantages and healthy growth trajectories, particularly the Life Sciences business in China which continued to perform well with reagents growing solidly above overall reagents performance last year despite the immunodiagnostic headwinds. Furthermore, the company is positioned to capitalize on structural inflection points in AI-driven life sciences research, where every AI-generated discovery requires physical validation through wet lab experimentation – creating a demand bottleneck for Revvity's core offerings in consumables, instruments, and software that translate computational insights into biological validation. The internal AI deployment, highlighted by Gartner research as differentiated and cost-effective, is accelerating software delivery and enabling previously infeasible initiatives at a fraction of traditional implementation costs, with employee adoption rates well above corporate averages, signaling immediate operational efficiency gains that will compound as cost productivity initiatives fully roll out by midyear, driving margin expansion starting in the second half of 2026 and annualizing into robust first-half 2027 performance. Recent FDA clearance for Revvity's Total Testosterone automated chemiluminescence immunoassay completes a first-of-its-kind testosterone diagnostics portfolio on a single platform, streamlining workflow and replacing complex ED-LC/MS methods, which addresses a critical unmet need in endocrine disorders and expands the company's reproductive health franchise beyond its current strength in newborn screening and Genomics England contributions – a near-term catalyst management understated amid broader AI and software discussions. The combination of portfolio optimization, AI-driven demand inflection, operational efficiency execution, and new product launches in high-growth software (BioDesign, LabGistics, Xynthetica) creates a powerful convergence of catalysts that the market is underestimating as it focuses narrowly on near-term guidance ranges rather than the multi-year value creation phase of AI adoption in life sciences where Revvity holds enabling technologies.
Revvity's software segment, particularly the Signals business, is experiencing a hidden inflection point in adoption and monetization that is not fully captured by organic growth metrics due to acquisition-related revenue recognition timing, presenting a significant bullish catalyst for future revenue acceleration and margin expansion. While management noted organic growth for software is expected to be positive mid-single digits for the full year and acknowledged a 20% Q2 decline due to tough comps, they simultaneously highlighted robust SaaS and ARR growth north of 30% in Q1 and strong double-digit APV (Annualized Contract Value) growth, indicating that the underlying customer acquisition and contract value momentum is substantially stronger than organic growth suggests – a discrepancy driven by the timing of revenue recognition from recent acquisitions like ACD/Labs, which contributed 75 basis points to Q1 revenue growth but masks the true velocity of the software franchise. The excitement around upcoming launches – Xynthetica (AI models as a service), BioDesign (cloud-native molecular design for biologics), and LabGistics (AI-first drug discovery workflow) – represents a rare confluence of innovation where all three major software products are launching in a single year, creating a comprehensive suite that addresses critical needs in AI-driven preclinical R&D, from computational hypothesis generation to wet lab validation workflows, with BioDesign being the only cloud-based offering of its type at launch, positioning Revvity to capture early-mover advantage in a rapidly expanding market. This software-led growth is further amplified by the company's differentiated internal AI adoption strategy, which uses a structured approach to deploy multiple leading LLMs across the global employee base at a fraction of traditional corporate AI costs, yielding productivity gains that are already accelerating software delivery and enabling impactful initiatives – a cost-efficient engine for innovation that management believes will have a remarkable cost-out impact in the mid- to longer term, directly contributing to operating margin expansion beyond the current 28.4% pro forma target as these initiatives scale and anniversary through 2027. The market is overlooking how this software innovation cycle, combined with the secular tailwind of AI increasing demand for biological validation tools, creates a self-reinforcing loop: AI-generated therapeutic hypotheses drive demand for wet lab experimentation (Revvity's core), which in turn generates new data that improves AI models, thereby increasing the value of Revvity's software and instrument offerings that facilitate this cycle – a virtuous cycle where the company sits at the nexus of value creation in the AI adoption journey, with significant upside potential as the market transitions from infrastructure build-out to value capture phase, where customers realize returns on AI investments through faster timelines and higher success rates, incentivizing even greater investment in research capabilities and expanding the total addressable market for scientific tools. This structural shift in how preclinical research is conducted – where AI accelerates hypothesis generation but physical validation remains irreplaceable – ensures sustained demand for Revvity's offerings regardless of short-term macroeconomic fluctuations, providing a durable growth runway that is not reflected in the conservative 3%-4% pro forma organic guidance for 2026.

▼ Bear case

Despite management's optimistic narrative on AI-driven demand and software innovation, Revvity faces significant near-term execution risks in its high-growth software segment that could delay or diminish the expected revenue and margin benefits, particularly as the company guides for a 20% organic decline in software during Q2 due to tough year-over-year comps from prior product launches and acquisitions, a stark contrast to the robust SaaS and ARR growth highlighted in Q1, suggesting that the underlying customer adoption may be more volatile or seasonal than management implies, and raising concerns about the sustainability of the double-digit APV growth trajectory if Q2 performance fails to inflect positively as anticipated in the second half of the year. The reliance on non-GAAP metrics like APV and SaaS growth to mask softer organic trends introduces transparency risks, especially given that the ACD/Labs acquisition contributed 75 basis points to Q1 revenue growth but its integration may be encountering unforeseen challenges in sales force alignment or product bundling that are not being disclosed, potentially undermining the expected synergies and creating execution risk in achieving the guided mid-single digit full-year software organic growth, let alone the high-teens H2 growth projection. Furthermore, while management emphasizes the structural opportunity in AI-driven life sciences research, the company's ability to monetize this trend depends on customers successfully translating AI-generated hypotheses into funded wet lab validation projects – a process that remains contingent on biotech and pharma R&D budgets, which, despite modest low single-digit growth in Q1, are still described by management as 'measured' as customers work through budget cycles, with no clear indication of a sustained inflection in upstream spending that would be necessary to fuel the predicted demand bottleneck for validation tools, leaving the AI opportunity vulnerable to macroeconomic headwinds or shifts in corporate research prioritization that could prolong the infrastructure build-out phase without transitioning to value capture. The recent FDA clearance for the Total Testosterone assay, while scientifically meaningful, addresses a niche segment within reproductive health and is unlikely to move the needle on overall company growth given that reproductive health represents only approximately 1%-1.5% of pro forma revenue post-divestiture, and management did not provide any quantifiable guidance uplift from this launch, suggesting its impact may be incremental at best rather than the transformative catalyst implied in the bullish case, especially when weighed against persistent global birth rate trends that continue to constrain the broader reproductive diagnostics market despite Revvity's specific tailwinds in rare disease testing. Additionally, the company's internal AI adoption strategy, while cost-effective, carries implementation risks including potential employee resistance to role repositioning, data privacy concerns from broad LLM deployment, and the challenge of measuring actual productivity gains beyond anecdotal feedback, with the promised 'remarkable' cost-out impact remaining unproven at scale and contingent on successful change management across a global workforce of 11,000 employees, introducing operational execution risk that could delay or reduce the anticipated margin expansion from these initiatives.
The pro forma financial improvements from the China immunodiagnostics divestiture, while presented as a permanent upgrade to the business profile, may be overstated due to unresolved risks in the transaction execution and the potential for the remaining China business to underperform expectations, particularly as management's optimism about Life Sciences growth in China relies on the assumption that the right products and policy backdrop will persist, despite acknowledging persistent policy-induced headwinds in the diagnostics segment and admitting that success in China requires appropriate market positioning – a vague qualifier that leaves room for execution risk if regulatory shifts or local competition disrupt the expected trajectory, especially given that the Life Sciences business in China, while currently performing well, represented a larger absolute revenue base than the divested immunodiagnostics segment last year, meaning any downturn here would have a material impact on the pro forma 8%-9% China revenue exposure that management views as acceptable. Furthermore, the guidance for pro forma 2026 organic growth of 3%-4% implies a significant step down from the Q1 pro forma organic growth of 6%, with management attributing this slowdown to conservative assumptions in the second half of the year for Life Science Solutions and Diagnostics, yet failing to provide concrete evidence of why these segments would decelerate when comps are not getting harder, raising concerns that the Q1 strength was driven by one-time factors such as inventory replenishment, timing of the Genomics England sample volumes (which were 'slightly ahead' of expectations but not quantified), or temporary pull-forward of demand from customers working through budget cycles, none of which were explicitly disavowed as non-recurring, suggesting the underlying run-rate growth may be closer to the guided 2%-3% Q2 range than the Q1 6% pro forma figure. The company's reliance on share buybacks as a primary capital deployment tool, while boosting EPS in the short term, raises concerns about diminished financial flexibility for strategic M&A or organic investment, especially as management admits there are no compelling large-scale opportunities and will continue to be 'opportunistic' on buybacks, potentially signaling a lack of confidence in internal growth projects to generate returns above the cost of capital, which could undermine long-term value creation if the buybacks are merely financial engineering rather than a reflection of genuine undervaluation. Finally, the updated pro forma guidance already incorporates a 20% reduction related to the planned divestiture in the EPS outlook ($5.20-$5.30), yet provides no offset from potential divestiture proceeds until 2027, meaning the full financial benefit of the transaction is delayed while the company absorbs the earnings dilution now, and any delay in closing beyond the expected 2027 timeline – which management acknowledges depends on regulatory approvals and buyer-led manufacturing localization – would prolong the period of elevated execution risk without the corresponding deleveraging or redeployment of capital, leaving the company vulnerable to prolonged pressure from the very structural challenges it sought to exit.

Despite management's optimistic narrative on AI-driven demand and software innovation, Revvity faces significant near-term execution risks in its high-growth software segment that could delay or diminish the expected revenue and margin benefits, particularly as the company guides for a 20% organic decline in software during Q2 due to tough year-over-year comps from prior product launches and acquisitions, a stark contrast to the robust SaaS and ARR growth highlighted in Q1, suggesting that the underlying customer adoption may be more volatile or seasonal than management implies, and raising concerns about the sustainability of the double-digit APV growth trajectory if Q2 performance fails to inflect positively as anticipated in the second half of the year. The reliance on non-GAAP metrics like APV and SaaS growth to mask softer organic trends introduces transparency risks, especially given that the ACD/Labs acquisition contributed 75 basis points to Q1 revenue growth but its integration may be encountering unforeseen challenges in sales force alignment or product bundling that are not being disclosed, potentially undermining the expected synergies and creating execution risk in achieving the guided mid-single digit full-year software organic growth, let alone the high-teens H2 growth projection. Furthermore, while management emphasizes the structural opportunity in AI-driven life sciences research, the company's ability to monetize this trend depends on customers successfully translating AI-generated hypotheses into funded wet lab validation projects – a process that remains contingent on biotech and pharma R&D budgets, which, despite modest low single-digit growth in Q1, are still described by management as 'measured' as customers work through budget cycles, with no clear indication of a sustained inflection in upstream spending that would be necessary to fuel the predicted demand bottleneck for validation tools, leaving the AI opportunity vulnerable to macroeconomic headwinds or shifts in corporate research prioritization that could prolong the infrastructure build-out phase without transitioning to value capture. The recent FDA clearance for the Total Testosterone assay, while scientifically meaningful, addresses a niche segment within reproductive health and is unlikely to move the needle on overall company growth given that reproductive health represents only approximately 1%-1.5% of pro forma revenue post-divestiture, and management did not provide any quantifiable guidance uplift from this launch, suggesting its impact may be incremental at best rather than the transformative catalyst implied in the bullish case, especially when weighed against persistent global birth rate trends that continue to constrain the broader reproductive diagnostics market despite Revvity's specific tailwinds in rare disease testing. Additionally, the company's internal AI adoption strategy, while cost-effective, carries implementation risks including potential employee resistance to role repositioning, data privacy concerns from broad LLM deployment, and the challenge of measuring actual productivity gains beyond anecdotal feedback, with the promised 'remarkable' cost-out impact remaining unproven at scale and contingent on successful change management across a global workforce of 11,000 employees, introducing operational execution risk that could delay or reduce the anticipated margin expansion from these initiatives.
The pro forma financial improvements from the China immunodiagnostics divestiture, while presented as a permanent upgrade to the business profile, may be overstated due to unresolved risks in the transaction execution and the potential for the remaining China business to underperform expectations, particularly as management's optimism about Life Sciences growth in China relies on the assumption that the right products and policy backdrop will persist, despite acknowledging persistent policy-induced headwinds in the diagnostics segment and admitting that success in China requires appropriate market positioning – a vague qualifier that leaves room for execution risk if regulatory shifts or local competition disrupt the expected trajectory, especially given that the Life Sciences business in China, while currently performing well, represented a larger absolute revenue base than the divested immunodiagnostics segment last year, meaning any downturn here would have a material impact on the pro forma 8%-9% China revenue exposure that management views as acceptable. Furthermore, the guidance for pro forma 2026 organic growth of 3%-4% implies a significant step down from the Q1 pro forma organic growth of 6%, with management attributing this slowdown to conservative assumptions in the second half of the year for Life Science Solutions and Diagnostics, yet failing to provide concrete evidence of why these segments would decelerate when comps are not getting harder, raising concerns that the Q1 strength was driven by one-time factors such as inventory replenishment, timing of the Genomics England sample volumes (which were 'slightly ahead' of expectations but not quantified), or temporary pull-forward of demand from customers working through budget cycles, none of which were explicitly disavowed as non-recurring, suggesting the underlying run-rate growth may be closer to the guided 2%-3% Q2 range than the Q1 6% pro forma figure. The company's reliance on share buybacks as a primary capital deployment tool, while boosting EPS in the short term, raises concerns about diminished financial flexibility for strategic M&A or organic investment, especially as management admits there are no compelling large-scale opportunities and will continue to be 'opportunistic' on buybacks, potentially signaling a lack of confidence in internal growth projects to generate returns above the cost of capital, which could undermine long-term value creation if the buybacks are merely financial engineering rather than a reflection of genuine undervaluation. Finally, the updated pro forma guidance already incorporates a 20% reduction related to the planned divestiture in the EPS outlook ($5.20-$5.30), yet provides no offset from potential divestiture proceeds until 2027, meaning the full financial benefit of the transaction is delayed while the company absorbs the earnings dilution now, and any delay in closing beyond the expected 2027 timeline – which management acknowledges depends on regulatory approvals and buyer-led manufacturing localization – would prolong the period of elevated execution risk without the corresponding deleveraging or redeployment of capital, leaving the company vulnerable to prolonged pressure from the very structural challenges it sought to exit.

Major goods/service lines Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Major goods/service lines Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Major goods/service lines Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password